Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

New Amsterdam Sciences

New Amsterdam Sciences?uq=PEM9b6PF
2012 FOUNDED
PRIVATE STATUS
Angel LATEST DEAL TYPE
$250K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of anti-idiopathic pulmonary fibrosis drug. The company develops anti-idiopathic pulmonary fibrosis drug which is used in curing influenza infection, solid tumors and helps in wound healing.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 14362 North Frank Lloyd Wright Boulevard
  • Suite 1000
  • Scottsdale, AZ 85260
  • United States

+1 (480) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore New Amsterdam Sciences’s full profile, request a free trial.

New Amsterdam Sciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 19-Nov-2015 $250K 00000 Completed Startup
1. Grant 11-Mar-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

New Amsterdam Sciences Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institutes of Health Government Minority 000 0000 000000 0

New Amsterdam Sciences Executive Team (1)

Name Title Board
Seat
Contact
Info
Jerry Toepfer Founder & Vice President

New Amsterdam Sciences Board Members (3)

Name Representing Role Since Contact
Info
Jill Anderson JD New Amsterdam Sciences Board Member 000 0000
Michael Wilhelm New Amsterdam Sciences Board Member, Chief Executive Officer & Director of Strategic Partnering and Public Relations 000 0000
Theodore Staahl MD New Amsterdam Sciences Board Member 000 0000